Cellebrite DI (NASDAQ:CLBT) Given New $14.00 Price Target at Needham & Company LLC

Cellebrite DI (NASDAQ:CLBT) had its target price boosted by Needham & Company LLC from $12.50 to $14.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. cut their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Weiss Ratings lowered Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. Lake Street Capital dropped their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, DA Davidson reaffirmed a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a research note on Tuesday, September 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Cellebrite DI Trading Down 14.3%

Shares of NASDAQ CLBT opened at $10.89 on Thursday. The stock has a market cap of $2.72 billion, a PE ratio of 49.50, a P/E/G ratio of 1.95 and a beta of 1.06. Cellebrite DI has a 12-month low of $9.58 and a 12-month high of $19.98. The company has a 50-day moving average of $11.61 and a 200 day moving average of $13.24.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, November 12th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.08. The business had revenue of $149.02 million for the quarter, compared to analyst estimates of $145.83 million. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. On average, sell-side analysts forecast that Cellebrite DI will post 0.37 EPS for the current fiscal year.

Insider Activity

In other news, CMO David Gee sold 4,323 shares of Cellebrite DI stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $11.36, for a total transaction of $49,109.28. Following the sale, the chief marketing officer owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. The trade was a 3.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Marcus Jewell sold 12,562 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the transaction, the executive owned 427,128 shares in the company, valued at $4,800,918.72. This represents a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 56,909 shares of company stock valued at $641,890. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. lifted its stake in shares of Cellebrite DI by 59.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock valued at $103,000 after purchasing an additional 2,785 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in Cellebrite DI by 93.3% in the 3rd quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company’s stock valued at $66,000 after buying an additional 2,816 shares during the period. Pacer Advisors Inc. raised its holdings in Cellebrite DI by 91.1% in the 1st quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after buying an additional 3,626 shares during the period. Moody National Bank Trust Division raised its holdings in Cellebrite DI by 7.6% in the 2nd quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock valued at $886,000 after buying an additional 4,284 shares during the period. Finally, Quantinno Capital Management LP acquired a new position in Cellebrite DI in the first quarter valued at about $150,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Top Cellebrite DI Stories

Investors following CLBT have been watching these stories:

• Positive Sentiment: Q3 revenue was $149.0 million, above the $145.8 million analyst estimate, while EPS was $0.17. The company also reported 20% ARR growth, $26.7 million in net income, and a 31% trailing-twelve-month free-cash-flow margin. Cellebrite Reports Third-Quarter 2026 Results
• Neutral Sentiment: Full-year 2026 revenue guidance of $553 million to $558 million is broadly in line with the $556.8 million consensus estimate.
• Negative Sentiment: Q4 revenue guidance of $145 million to $150 million fell short of the $151.6 million analyst consensus. This cautious near-term outlook may be outweighing the Q3 beat and growth metrics.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.